Filing Details

Accession Number:
0001415889-25-007034
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-03-05 18:02:28
Reporting Period:
2025-03-03
Filing Date:
2025-03-05
Accepted Time:
2025-03-05 18:02:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1127537 Pulmonx Corp LUNG Surgical & Medical Instruments & Apparatus (3841) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1804146 Beran Geoffrey Rose C/O Pulmonx Corporation
700 Chesapeake Drive
Redwood City CA 94063
Chief Commercial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2025-03-03 520 $7.12 290,537 No 4 S Direct
Common Stock Disposition 2025-03-03 915 $7.12 289,622 No 4 S Direct
Common Stock Disposition 2025-03-03 2,327 $7.14 287,295 No 4 S Direct
Common Stock Disposition 2025-03-03 2,017 $7.12 285,278 No 4 S Direct
Common Stock Acquisiton 2025-03-03 108,000 $0.00 393,278 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 A Direct
Footnotes
  1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021.
  2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022.
  3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
  4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
  5. Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 3, 2025.